Pharmaceutical Technology

JUNE 8, 2023

The company’s samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses. of these are in the pre-clinical stage.

Vaccination 130

Vaccination Vaccine Immune Response Allergies 130

Drug Discovery World

JULY 19, 2022

The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus. The vaccine is based on a messenger RNA (mRNA) platform. .

Clinical Trials 52

Clinical Trials Clinical Trials Trials Vaccination 52

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Now, the HIV research community is setting its sights on vaccines that are in earlier stages of development, based on new approaches like messenger RNA (mRNA) -based vaccines or those using human cytomegalovirus (HCMV) vectors.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. In a study where the antiviral activity of Sunlenca was evaluated in combination with an optimized background regimen, 87.5 percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

OCTOBER 24, 2022

However, there was also controversy as researchers faced a backlash from the National Institute of Allergy and Infectious Diseases for their study which created a hybrid version of Covid-19. You can listen below, or find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts. .

Allergies 40

Allergies Drugs Research RNA 40

pharmaphorum

APRIL 28, 2021

The RNA interference (RNAi) drug is designed to treat haemophilia A and B patients by suppressing antithrombin (AT), a protein that inhibits blood clotting. The aim is to increase the generation of thrombin – a major component of the clotting cascade – and normalise clot formation.

Drugs 52

Drugs Sales Allergies RNA 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Scienmag

JULY 2, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses — most […].

Vaccination 40

Vaccination Vaccine RNA Research 40

The Pharma Data

NOVEMBER 16, 2020

and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. It combines Moderna’s mRNA (messenger RNA) delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID scientists. National Institutes of Health to respond to the global pandemic.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Drug Discovery World

JANUARY 21, 2024

Protein and RNA-based therapeutics development is a challenging multidimensional problem, accompanied by an equally challenging scalable manufacturing process. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Protein 52

Protein Vaccination Vaccine Development 52

The Pharma Data

NOVEMBER 17, 2020

developed its vaccine in collaboration with researchers from the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. Food and Drug Administration has said that coronavirus vaccines should be at least 50 percent effective to be approved. Moderna, based in Cambridge, Mass.,

Vaccination 52

Vaccination Vaccine RNA Allergies 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Dec. million to 7.5

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

Pharmaceutical Technology

JULY 18, 2022

Moderna has received provisional registration from the Australian Therapeutic Goods Administration (TGA) for its messenger RNA (mRNA) Covid-19 vaccine, Spikevax, for kids aged six months to five years. The 25µg two-dose vaccine regimen is indicated for active immunisation for the prevention of Covid-19.

Vaccination 246

Vaccination Vaccine Gene Therapy Antibody 246

NY Times

NOVEMBER 30, 2020

The first shots could be given as early as Dec. 21, if authorization is granted.

Vaccination 145

Vaccination Vaccine RNA Allergies 145

Roots Analysis

MARCH 16, 2023

The following points illustrate the key applications of mRNA therapeutics and vaccines: Allergy Tolerization Therapies: Plasmid DNA and mRNA vaccines that encode for allergens have been demonstrated to be capable of inducing T helper 1 cells and T regulatory responses, which, in turn, can modulate allergic reactions caused due to T helper 2 cells.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Drug Discovery World

FEBRUARY 6, 2024

In the morning, Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH, gave a fascinating talk on ‘Structural vaccinology for influenza: The technology behind the NIAD VRC’s nanoparticle-based vaccines.’

Life Science 64

Life Science Genome Genomics RNA 64

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. Both influenza and SARS-CoV-2 have RNA as their genetic material. An RNA genome enables the genetic material to mutate more rapidly.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

The Pharma Data

NOVEMBER 16, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. CAMBRIDGE, Mass.–(BUSINESS

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Drug Discovery World

AUGUST 1, 2022

This technology defines gene expression patterns from rare cells harbouring latent HIV by generating millions of single-cell reaction containers in the form of water-in-oil emulsions, in which messenger RNA capture and virus DNA detection can be performed sequentially while maintaining segregation among cells.

Gene Expression 52

Gene Expression Scientist Gene Allergies 52

The Pharma Data

DECEMBER 21, 2020

Galidesivir treatment was associated with a more rapid decline in viral RNA levels in the respiratory tract in an apparent dose-dependent manner. About Galidesivir (BCX4430) Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase.

RNA 52

RNA Clinical Trials Clinical Trials Trials 52

The Pharma Data

DECEMBER 31, 2020

The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. These reactions can be treated, and most patients with allergies can still get the vaccine. Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273.

Vaccination 52

Vaccination Vaccine FDA Approval Hormones 52

The Pharma Data

JANUARY 4, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

XTalks

AUGUST 2, 2023

2) Veklury (remdesivir) Veklury, approved by the FDA in 2020, is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor designed for the treatment of COVID-19. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. Veklury generated a revenue of $3.91 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

NOVEMBER 2, 2022

The first participant has been dosed in a Phase 1 trial evaluating the safety, tolerability, and immunogenicity of a nucleoside-modified RNA (modRNA)-based combination vaccine approach. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. have a fever.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

XTalks

DECEMBER 24, 2020

However, regulators are warning people with allergies to polyethylene glycol (PEG), an excipient in Pfizer’s vaccine, not to get vaccinated just yet. Single-Cell RNA Sequencing. Among these, single-cell RNA sequencing (scRNA-seq) is particularly useful for analyzing the transcriptome with respect to gene expression.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

OCTOBER 30, 2020

Veklury is a nucleotide analog RNA polymerase inhibitor and works by stopping replication of SARS-CoV-2. Rash, allergy and infusion site reactions may also occur. Previously approved under an Emergency Use Authorization (EUA), Veklury is now fully cleared for the treatment of hospitalized patients with COVID-19.

FDA Approval 52

FDA Approval Trials Allergies RNA 52

The Pharma Data

DECEMBER 23, 2020

One person familiar with the list said it included the lipids that encase the RNA material in both the Moderna and Pfizer vaccines, the Times reported. The deal calls for the government to invoke the Defense Production Act to give the company better access to roughly nine specialized products it needs to make the vaccine.

Vaccination 52

Vaccination Vaccine Allergies Nurses 52

XTalks

SEPTEMBER 14, 2020

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. Fujifilm Favipiravir (Avigan) Inhibits RNA-dependent RNA polymerase.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

The Pharma Data

DECEMBER 28, 2020

One person familiar with the list said it included the lipids that encase the RNA material in both the Moderna and Pfizer vaccines, the Times reported. National Institute of Allergy and Infectious Diseases, said last week. “It very well might be here for all we know.”

Vaccination 52

Vaccination Vaccine Scientist Allergies 52